94 related articles for article (PubMed ID: 6354063)
21. Blood group isoantigens ABO (H) in transitional carcinoma of the bladder: a clinicopathological study.
Cuadrado E; Rodriguez-Trinidad A; Blasco E; Torrado J; Lopez Garcia JA; Arozena F
J Urol; 1986 Feb; 135(2):409-15. PubMed ID: 3511295
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
Mizutani Y; Okada Y; Terachi T; Yoshida O
J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
[TBL] [Abstract][Full Text] [Related]
23. Prognosis in carcinoma of the urinary bladder based upon tissue blood group abh and Thomsen-Friedenreich antigen status and karyotype of the initial tumor.
Summers JL; Coon JS; Ward RM; Falor WH; Miller AW; Weinstein RS
Cancer Res; 1983 Feb; 43(2):934-9. PubMed ID: 6848204
[TBL] [Abstract][Full Text] [Related]
24. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression.
King ED; Matteson J; Jacobs SC; Kyprianou N
J Urol; 1996 Jan; 155(1):316-20. PubMed ID: 7490878
[TBL] [Abstract][Full Text] [Related]
25. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
26. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder.
Rosen EM; Joseph A; Jin L; Yao Y; Chau MH; Fuchs A; Gomella L; Hastings H; Goldberg ID; Weiss GH
J Urol; 1997 Jan; 157(1):72-8. PubMed ID: 8976219
[TBL] [Abstract][Full Text] [Related]
27. Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation.
Fong A; Garcia E; Gwynn L; Lisanti MP; Fazzari MJ; Li M
Am J Clin Pathol; 2003 Jul; 120(1):93-100. PubMed ID: 12866378
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of denuded urothelium in bladder biopsy.
Levi AW; Potter SR; Schoenberg MP; Epstein JI
J Urol; 2001 Aug; 166(2):457-60. PubMed ID: 11458047
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
30. [Usefulness of P53 oncoprotein in urinary wash cytology: experience in patients with superficial bladder carcinoma].
Moreno Sierra J; Luengo Alpuente S; López García-Asenjo J; Redondo González E; Blanco Jiménez E; Fernández Pérez C; Silmi Moyano A; Resel Estévez L
Arch Esp Urol; 1999 Nov; 52(9):943-54. PubMed ID: 10633962
[TBL] [Abstract][Full Text] [Related]
31. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
32. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma.
Genega EM; Hutchinson B; Reuter VE; Gaudin PB
Mod Pathol; 2000 Nov; 13(11):1186-91. PubMed ID: 11106075
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
34. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
[TBL] [Abstract][Full Text] [Related]
35. Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy.
Leach FS; Hsieh JT; Molberg K; Saboorian MH; McConnell JD; Sagalowsky AI
Cancer; 2000 May; 88(10):2333-41. PubMed ID: 10820356
[TBL] [Abstract][Full Text] [Related]
36. [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder].
Leng J; Zhang Y; Yao X; Wen K
Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):40-3. PubMed ID: 11831985
[TBL] [Abstract][Full Text] [Related]
37. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression.
Mhawech P; Greloz V; Oppikofer C; Szalay-Quinodoz I; Herrmann F
Cancer; 2004 Jun; 100(11):2367-75. PubMed ID: 15160340
[TBL] [Abstract][Full Text] [Related]
38. Expression of CD44s and CD44v6 in transitional cell carcinomas of the urinary bladder: comparison with tumour grade, proliferative activity and p53 immunoreactivity of tumour cells.
Kuncová J; Urban M; Mandys V
APMIS; 2007 Nov; 115(11):1194-205. PubMed ID: 18092951
[TBL] [Abstract][Full Text] [Related]
39. Plasmacytoid transitional cell carcinoma of urinary bladder: a clinicopathologic study of 9 cases.
Ro JY; Shen SS; Lee HI; Hong EK; Lee YH; Cho NH; Jung SJ; Choi YJ; Ayala AG
Am J Surg Pathol; 2008 May; 32(5):752-7. PubMed ID: 18379419
[TBL] [Abstract][Full Text] [Related]
40. Percutaneous management of renal pelvic urothelial tumors: long-term followup.
Goel MC; Mahendra V; Roberts JG
J Urol; 2003 Mar; 169(3):925-9; discussion 929-30. PubMed ID: 12576814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
